Clinical Trials
5 trialsNCT03107988 2025-09-15
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT04800822 2024-10-22
PF-07284892 in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT03726333 2024-06-21
Hepatic Impairment Study for Lorlatinib in Cancer Patients
Pfizer
Phase 1 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04541407 2023-05-16
Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease
University of Colorado, Denver
Phase 1 Completed